metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

breast cancer HER 2 negative
es-BC - HER2 negative - (neo)adjuvant (NA) 1
mBC - HER 2 negative 1

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs paclitaxel followed by doxorubicin plus cyclophosphamide

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open